New York, June 2, 2026, 04:18 EDT
- Genprex traded at $0.7501 early Tuesday, giving the company a market value of around $7.9 million.
- The stock dropped 3.77% Monday, hitting a low of $0.72 during the session.
- Investors look at a muted ASCO biomarker read but also see trial risk, cash needs and possible dilution.
Genprex Inc. stock stayed close to Monday’s low before the next U.S. trading session, keeping the Nasdaq Capital Market gene therapy name below $1. Investors were watching new lung-cancer biomarker data, while funding remained a concern. June 2 isn’t on the Nasdaq’s 2026 market holiday schedule.
GNPX was last quoted at $0.7501, about 4% lower than its previous close. That puts the company’s market cap near $7.9 million. Monday’s session saw the stock drop 3.77%, opening at $0.78, hitting a high of $0.79, and bottoming at $0.72 before closing at $0.75. About 401,000 shares changed hands.
Timing is in focus. The American Society of Clinical Oncology meeting goes on in Chicago through Tuesday, and Genprex is moving on an abstract about Reqorsa, its lead gene therapy for lung cancer. With a company like this, any positive clinical sign can be meaningful, but management still needs to get bigger trials done, refine which patients qualify, and make sure funding keeps the work going.
Genprex said in a May 26 filing that collaborators’ ASCO abstract looked at predictive biomarkers in patients treated with quaratusugene ozeplasmid, or Reqorsa. Progression-free survival is how long patients live before their disease gets worse.
Trop-2 H-scores above 100 and PTEN H-scores below 100 tracked with longer PFS for non-small cell lung cancer patients, according to the filing. An H-score looks at protein staining strength and amount in tumor tissue. Results came from 18 patients and three studies. In small cell lung cancer, the same biomarkers weren’t as useful; Trop-2 wasn’t evaluable and PTEN didn’t link to longer PFS.
Ryan Confer, president and CEO at Genprex, said the results are a “substantial leap forward for personalized medicine in lung cancer.” Chief Medical Officer Mark S. Berger said more work studying staining intensity could mean “more concrete data for optimized patient selection.” Genprex
Genprex faces stiff competition but sees opportunity in that. The company isn’t trying to replace leading lung cancer drugs tested in its trials. Instead, Genprex is looking to combine its therapy with those drugs. The Acclaim-1 trial tests Reqorsa with AstraZeneca’s Tagrisso, and Acclaim-3 pairs it with Genentech’s Tecentriq. This puts Genprex’s approach alongside big names in oncology.
Genprex reported a first-quarter net loss of $4.46 million and held $18.05 million in cash and cash equivalents as of March 31. The company said it doesn’t have any current revenue and expects its cash will cover needed operations and clinical trial work into the second half of 2027. Genprex said it will need more capital.
But there are clear risks. The biomarker analysis was limited, the small cell lung cancer result didn’t hold up, and a bigger trial might not repeat the link. Genprex also flagged ongoing losses and said it needs more funding, which could threaten its ability to keep operating. Further share sales may also dilute current holders.
Tuesday’s trade isn’t hinging on one headline, but on whether momentum holds. With shares under $1, Genprex still has to convince investors the ASCO data can improve trial design. It also has to show it can fund operations without drowning out any clinical signal.
